Funder: National Institutes of Health

Due Dates: May 19, 2025 (Letter of Intent) | June 18, 2025 (New) | July 18, 2025 (Renewal/Resubmission/Revision) | August 8, 2025 (Letter of Intent) | September 7, 2025 (AIDS-related) | September 8, 2025 (Expiration)

Funding Amounts: No budget cap; UG3 phase up to 2 years, UH3 phase up to 5 years; budgets must reflect actual project needs.

Summary: Supports investigator-initiated prospective observational comparative effectiveness research in clinical neurosciences aligned with NINDS priorities.

Key Information: Only prospective observational studies are eligible; clinical trials are not allowed; updated March 31, 2025—review full NOFO for changes.